MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • PSivida Corp. (PSDV) Announces Austria Has Granted Marketing Authorization To ILUVIEN® For The Treatment Of Chronic Diabetic Macular Edema 0 comments
    Apr 25, 2012 2:31 PM | about stocks: PSDV

    pSivida Corp., a leader in developing sustained release drug delivery products for treatment of back-of-the-eye diseases, announced yesterday that ILUVIEN® has been granted marketing authorization from the Austrian Agency for Health and Food Safety (Osterreichische Agentur fur Gesundheit und Ernahrungssicherheit, AGES). ILUVIEN® is used in the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered unsatisfactorily responsive to available therapies.

    This marketing authorization comes on the heels of the completion of the Decentralized Regulatory Procedure. In this procedure the Medicines and Healthcare products Regulatory Agency in the United Kingdom delivered a positive outcome for ILUVIEN along with the six Concerned Members States of Austria, France, Germany, Italy, Spain, and Portugal. Austria gave ILUVIEN® its first national approval in the EU. Alimera expects further approvals to come soon and ILUVIEN® to be available in the EU by the end of 2012.

    "We are very pleased ILUVIEN has received this marketing authorization and will soon be available to patients in Austria," said Dr. Paul Ashton, president and chief executive officer of pSivida. "We look forward to ILUVIEN receiving the additional expected EU approvals."

    The International Diabetes Federation estimates that approximately 750,000 people are currently living with diabetes in Austria, and Alimera estimates more than 40,000 people suffer from DME and could potentially benefit from the use of ILUVIEN®.

    For more information, please visit www.psivida.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: PSDV
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.